Evidence map›Paper›PMID 40183543›Full record

ArticleJournal of virology2025

Targeting USP22 to promote K63-linked ubiquitination and degradation of SARS-CoV-2 nucleocapsid protein.

Xin Xiao, Shifeng Li, Zhijin Zheng, Yingying Ji, Qian Du, Yibo Zuo, Ying Miao, Yukang Yuan, Hui Zheng, Fang Huang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xin XiaoDepartment of Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Shifeng LiDepartment of Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Zhijin ZhengInternational Institute of Infection and Immunity, Institutes of Biology and Medical Sciences (IBMS), Collaborative Innovation Center of Hematology, MOE Key Laboratory of Geriatric Disease and Immunology of Ministry of Education of China, School of Medicine, Soochow University, Suzhou, Jiangsu, China.
Yingying JiDepartment of Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.
Qian DuInternational Institute of Infection and Immunity, Institutes of Biology and Medical Sciences (IBMS), Collaborative Innovation Center of Hematology, MOE Key Laboratory of Geriatric Disease and Immunology of Ministry of Education of China, School of Medicine, Soochow University, Suzhou, Jiangsu, China.
Yibo ZuoInternational Institute of Infection and Immunity, Institutes of Biology and Medical Sciences (IBMS), Collaborative Innovation Center of Hematology, MOE Key Laboratory of Geriatric Disease and Immunology of Ministry of Education of China, School of Medicine, Soochow University, Suzhou, Jiangsu, China.
Ying MiaoDepartment of Laboratory Medicine, Institute of Laboratory Medicine, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Yukang YuanInternational Institute of Infection and Immunity, Institutes of Biology and Medical Sciences (IBMS), Collaborative Innovation Center of Hematology, MOE Key Laboratory of Geriatric Disease and Immunology of Ministry of Education of China, School of Medicine, Soochow University, Suzhou, Jiangsu, China.
Hui ZhengDepartment of Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID 0000-0002-4325-4946
Fang HuangDepartment of Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID 0000-0002-2227-4761
Jun WangDepartment of Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, China.ORCID 0000-0001-8708-3096

Funding

Natural Science Foundation of Jiangsu Province BK20241798Science Foundation of Jiangsu Commission of Health M2022086Suzhou Basic Research Project SSD2024053Suzhou Science and Technology Development Plan SKJYD2021073
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) generally hijacks the cellular machinery of host cells for survival. However, how SARS-CoV-2 employs the host's deubiquitinase to facilitate virus replication remains largely unknown. In this study, we identified the host deubiquitinase USP22 as a crucial regulator of the expression of SARS-CoV-2 nucleocapsid protein (SARS-CoV-2 NP), which is essential for SARS-CoV-2 replication. We demonstrated that SARS-CoV-2 NP proteins undergo ubiquitination-dependent degradation in host cells, while USP22 interacts with SARS-CoV-2 NP and downregulates K63-linked polyubiquitination of SARS-CoV-2 NP, thereby protecting SARS-CoV-2 NP from degradation. Importantly, we further revealed that sulbactam, an antibiotic, can reduce USP22 protein levels, eventually promoting the degradation of SARS-CoV-2 NP

Indexed as

Coronavirus Nucleocapsid ProteinsPhosphoproteinsSARS-CoV-2Ubiquitin ThiolesteraseAnimalsChlorocebus aethiopsCOVID-19HEK293 CellsHost-Pathogen InteractionsHumansMiceProteolysisUbiquitinationVero CellsVirus ReplicationCoronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsUbiquitin ThiolesteraseUsp22 protein, humandeubiquitinationSARS-CoV-2 NPsulbactamUSP22viral infection

Identifiers

PMID40183543
PMCPMC12090743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.